Tocilizumab administration in cytokine release syndrome is associated with hypofibrinogenemia after chimeric antigen receptor T-cell therapy for hematologic malignancies
Article Details
-
Date Published
September 12, 2024
Perl M, Herfeld K, Harrer DC, Hopting M, Schweiger M, Sterz U, Knodler L, Heimerl S, Hansmann L, Herr W, Poeck H, Wolff D, Edinger M, Hart C, Fante MA. Tocilizumab administration in cytokine release syndrome is associated with hypofibrinogenemia after chimeric antigen receptor T-cell therapy for hematologic malignancies. Haematologica. 2024 Sep 1. 109:2969-2977. doi:10.3324/haematol.2023.284564. PMID: 38546698